SG157224A1
(en)
|
2001-11-13 |
2009-12-29 |
Univ Pennsylvania |
A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
|
US9233131B2
(en)
|
2003-06-30 |
2016-01-12 |
The Regents Of The University Of California |
Mutant adeno-associated virus virions and methods of use thereof
|
US9441244B2
(en)
|
2003-06-30 |
2016-09-13 |
The Regents Of The University Of California |
Mutant adeno-associated virus virions and methods of use thereof
|
DK3211085T3
(da)
|
2003-09-30 |
2021-06-21 |
Univ Pennsylvania |
Klader af adeno-associeret virus (aav), sekvenser, vektorer indeholdende disse og anvendelser deraf
|
DK2359867T3
(en)
*
|
2005-04-07 |
2015-01-05 |
Univ Pennsylvania |
A method for increasing an AAV vector function
|
US9198984B2
(en)
|
2006-04-28 |
2015-12-01 |
The Trustees Of The University Of Pennsylvania |
Scalable production method for AAV
|
WO2007149852A2
(en)
*
|
2006-06-19 |
2007-12-27 |
Asklepios Biopharmaceutical, Inc. |
Modified factor viii and factor ix genes and vectors for gene therapy
|
US9725485B2
(en)
|
2012-05-15 |
2017-08-08 |
University Of Florida Research Foundation, Inc. |
AAV vectors with high transduction efficiency and uses thereof for gene therapy
|
DK2191001T3
(en)
|
2007-04-09 |
2016-09-19 |
Univ Florida |
RAAV VECTOR COMPOSITIONS WITH TYROSIN MODIFIED CAPSIDE PROTEINS AND PROCEDURES FOR USE THEREOF
|
MX2010012592A
(es)
|
2008-05-20 |
2011-05-05 |
Eos Neuroscience Inc |
Vectores para la administracion de proteinas sensibles a la luz y metodos de uso de las mismas.
|
US9217155B2
(en)
|
2008-05-28 |
2015-12-22 |
University Of Massachusetts |
Isolation of novel AAV'S and uses thereof
|
US11219696B2
(en)
|
2008-12-19 |
2022-01-11 |
Nationwide Children's Hospital |
Delivery of polynucleotides using recombinant AAV9
|
US10920244B2
(en)
|
2009-04-30 |
2021-02-16 |
The Trustees Of The University Of Pennsylvania |
Compositions for targeting conducting airway cells comprising adeno-associated virus constructs
|
US8734809B2
(en)
|
2009-05-28 |
2014-05-27 |
University Of Massachusetts |
AAV's and uses thereof
|
WO2011038187A1
(en)
|
2009-09-25 |
2011-03-31 |
The Trustees Of The University Of Pennsylvania |
Controlled adeno-associated virus (aav) diversification and libraries prepared therefrom
|
CA2793633A1
(en)
|
2010-03-29 |
2011-10-13 |
The Trustees Of The University Of Pennsylvania |
Pharmacologically induced transgene ablation system
|
US9315825B2
(en)
|
2010-03-29 |
2016-04-19 |
The Trustees Of The University Of Pennsylvania |
Pharmacologically induced transgene ablation system
|
WO2011133874A1
(en)
|
2010-04-23 |
2011-10-27 |
University Of Massachusetts |
Multicistronic expression constructs
|
EP3444346B1
(de)
|
2010-04-23 |
2022-07-27 |
University of Massachusetts |
Aav-basierte behandlung von cholesterinerkrankungen
|
DK2561073T3
(en)
|
2010-04-23 |
2016-12-12 |
Univ Massachusetts |
Aav vectors targeted to central nervous system and methods of use thereof
|
CA3128549A1
(en)
|
2010-07-12 |
2012-01-19 |
Universitat Autonoma De Barcelona |
Gene therapy composition for use in diabetes treatment
|
US8663624B2
(en)
|
2010-10-06 |
2014-03-04 |
The Regents Of The University Of California |
Adeno-associated virus virions with variant capsid and methods of use thereof
|
WO2012057363A1
(ja)
*
|
2010-10-27 |
2012-05-03 |
学校法人自治医科大学 |
神経系細胞への遺伝子導入のためのアデノ随伴ウイルスビリオン
|
EP2699688A1
(de)
|
2011-04-20 |
2014-02-26 |
The Trustees Of The University Of Pennsylvania |
Dosierpläne und zusammensetzungen zur aav-vermittelten passiven immunisierung von luftbürtigen krankheitserregern
|
WO2012145624A2
(en)
|
2011-04-21 |
2012-10-26 |
University Of Massachusetts |
Raav-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
|
EP3693025B1
(de)
|
2011-04-22 |
2021-10-13 |
The Regents of The University of California |
Adenoassoziierte virus-virionen mit veränderlichem kapsid und verwendungsverfahren dafür
|
US20130039888A1
(en)
|
2011-06-08 |
2013-02-14 |
Nationwide Children's Hospital Inc. |
Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders
|
AU2013221212B2
(en)
*
|
2012-02-17 |
2018-08-09 |
The Children's Hospital Of Philadelphia |
AAV vector compositions and methods for gene transfer to cells, organs and tissues
|
MY172457A
(en)
*
|
2012-04-18 |
2019-11-26 |
Childrens Hospital Philadelphia |
Composition and methods for highly efficient gene transfer using aav capsid variants
|
TWI698240B
(zh)
|
2012-05-15 |
2020-07-11 |
澳大利亞商艾佛蘭屈澳洲私營有限公司 |
使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
|
US10294281B2
(en)
|
2012-05-15 |
2019-05-21 |
University Of Florida Research Foundation, Incorporated |
High-transduction-efficiency rAAV vectors, compositions, and methods of use
|
JP6314138B2
(ja)
|
2012-08-01 |
2018-04-18 |
ネイションワイド チルドレンズ ホスピタル |
組換えアデノ随伴ウイルス9の髄腔内送達
|
EP2692868A1
(de)
|
2012-08-02 |
2014-02-05 |
Universitat Autònoma De Barcelona |
Adenoassoziierte virale (AAV) Vektoren für die Transduktion von Fettgewebe
|
EP3738974A1
(de)
*
|
2012-09-28 |
2020-11-18 |
The University of North Carolina at Chapel Hill |
Gegen oligodendrozyten gerichtete aav-vektoren
|
EP3747998A1
(de)
|
2013-03-15 |
2020-12-09 |
The Trustees of the University of Pennsylvania |
Zusammensetzungen zur behandlung von mpsi
|
US9719106B2
(en)
|
2013-04-29 |
2017-08-01 |
The Trustees Of The University Of Pennsylvania |
Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
|
KR102234672B1
(ko)
*
|
2013-05-21 |
2021-04-06 |
유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 |
캡시드-변형된 raav3 벡터 조성물, 및 인간 간암의 유전자 요법에서의 용도
|
US11136557B2
(en)
|
2013-05-31 |
2021-10-05 |
The Regents Of The University Of California |
Adeno-associated virus variants and methods of use thereof
|
CA3209883A1
(en)
*
|
2013-07-22 |
2015-01-29 |
The Children's Hospital Of Philadelphia |
Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues
|
WO2015048534A1
(en)
|
2013-09-26 |
2015-04-02 |
University Of Florida Research Foundation, Inc. |
Synthetic combinatorial aav capsid library for targeted gene therapy
|
EP3054995A1
(de)
*
|
2013-10-07 |
2016-08-17 |
Kiromic, LLC |
Zusammensetzungen und methoden zur behandlung kardiovaskulärer erkrankungen unter verwendung eines krankheitsspezifischen promotors
|
CN115141260A
(zh)
*
|
2013-10-11 |
2022-10-04 |
马萨诸塞眼科耳科诊所 |
预测祖先病毒序列的方法及其用途
|
GB201403684D0
(en)
*
|
2014-03-03 |
2014-04-16 |
King S College London |
Vector
|
WO2015127128A2
(en)
|
2014-02-19 |
2015-08-27 |
University Of Massachusetts |
Recombinant aavs having useful transcytosis properties
|
HUE051311T2
(hu)
|
2014-03-09 |
2021-03-01 |
Univ Pennsylvania |
Ornitin transzkarbamiláz (TC) deficiencia kezelésében alkalmas készítmények
|
EP3119798B1
(de)
|
2014-03-17 |
2020-08-05 |
Adverum Biotechnologies, Inc. |
Zusammensetzungen und verfahren zur verbesserten genexpression in zapfenzellen
|
WO2015143078A1
(en)
|
2014-03-18 |
2015-09-24 |
University Of Massachusetts |
Raav-based compositions and methods for treating amyotrophic lateral sclerosis
|
JP6741590B2
(ja)
|
2014-04-25 |
2020-08-19 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
コレステロールレベルを低下させるためのldlr変異体および組成物中でのそれらの使用
|
US10780182B2
(en)
|
2014-04-25 |
2020-09-22 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for treating metastatic breast cancer and other cancers in the brain
|
DK3137497T3
(da)
*
|
2014-05-02 |
2021-07-12 |
Genzyme Corp |
Aav-vektorer til retinal- og cns-genterapi
|
MY186389A
(en)
|
2014-05-13 |
2021-07-22 |
Univ Pennsylvania |
Compositions comprising aav expressing dual antibody constructs and uses thereof
|
WO2015191508A1
(en)
|
2014-06-09 |
2015-12-17 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
SG11201701033QA
(en)
*
|
2014-08-13 |
2017-03-30 |
Philadelphia Children Hospital |
An improved expression cassette for packaging and expression of variant factor viii for the treatment of hemostasis disorders
|
EP3194430A1
(de)
|
2014-09-16 |
2017-07-26 |
Universitat Autònoma De Barcelona |
Adeno-assoziierte virusvektoren zur gentheraüie von stoffwechselkrankheiten
|
WO2016054554A1
(en)
|
2014-10-03 |
2016-04-07 |
University Of Massachusetts |
Heterologous targeting peptide grafted aavs
|
EP3200830B1
(de)
|
2014-10-03 |
2020-09-09 |
University of Massachusetts |
Hocheffiziente bibliotheksidentifizierte aav-vektoren
|
CA2964272A1
(en)
|
2014-10-21 |
2016-04-28 |
Guangping Gao |
Recombinant aav variants and uses thereof
|
BR112017009497A2
(pt)
|
2014-11-05 |
2018-02-06 |
Voyager Therapeutics, Inc. |
polinucleotídeos de aadc para o tratamento da doença de parkinson
|
GB201420139D0
(en)
|
2014-11-12 |
2014-12-24 |
Ucl Business Plc |
Factor IX gene therapy
|
KR20230145206A
(ko)
|
2014-11-14 |
2023-10-17 |
보이저 테라퓨틱스, 인크. |
조절성 폴리뉴클레오티드
|
BR112017010087A2
(pt)
|
2014-11-14 |
2018-06-05 |
Voyager Therapeutics, Inc. |
composições e métodos para tratar esclerose lateral amiotrófica (ela)
|
MX2017006652A
(es)
|
2014-11-21 |
2017-08-21 |
Univ North Carolina Chapel Hill |
Vectores de virus adeno-asociado (aav) dirigidos al sistema nervioso central.
|
EP3230441A4
(de)
|
2014-12-12 |
2018-10-03 |
Voyager Therapeutics, Inc. |
Zusammensetzungen und verfahren zur herstellung von scaav
|
EP3233131A1
(de)
|
2014-12-16 |
2017-10-25 |
Board of Regents of the University of Nebraska |
Gentherapie für juvenile neuronale ceroid-lipofuszinose
|
EP3978614A3
(de)
|
2015-01-07 |
2022-07-27 |
Universitat Autònoma de Barcelona |
Einzelvektor-genkonstrukt mit insulin und glucokinasegenen
|
WO2016126857A1
(en)
|
2015-02-03 |
2016-08-11 |
University Of Florida Research Foundation, Inc. |
Recombinant aav1, aav5, and aav6 capsid mutants and uses thereof
|
US10676726B2
(en)
|
2015-02-09 |
2020-06-09 |
Duke University |
Compositions and methods for epigenome editing
|
EP3256170B1
(de)
|
2015-02-13 |
2020-09-23 |
University of Massachusetts |
Zusammensetzungen und verfahren zur transitorischen freisetzung von polypeptiden
|
EA201791939A1
(ru)
|
2015-03-02 |
2018-01-31 |
Адверум Байотекнолоджиз, Инк. |
Композиции и способы интравитреальной доставки полинуклеотидов в колбочки сетчатки
|
MX2017011615A
(es)
|
2015-03-10 |
2018-04-11 |
Univ Columbia |
Construcciones de vectores virales adeno-asociados de glut1 recombinantes y métodos relacionados para restablecer la expresión de glut1.
|
MX2017012097A
(es)
|
2015-03-24 |
2018-06-15 |
Univ California |
Variantes de virus adenoasociado y métodos de uso de estas.
|
US10555994B2
(en)
*
|
2015-03-30 |
2020-02-11 |
Boehringer Ingelheim Animal Health USA Inc. |
PCV2 ORF2 carrier platform
|
JP6851319B2
(ja)
|
2015-04-27 |
2021-03-31 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
ヒト疾患のCRISPR/Cas9媒介性の修正のためのデュアルAAVベクター系
|
US10881548B2
(en)
|
2015-05-07 |
2021-01-05 |
Massachusetts Eye And Ear Infirmary |
Methods of delivering an agent to the eye
|
WO2016200543A2
(en)
|
2015-05-13 |
2016-12-15 |
The Trustees Of The University Of Pennsylvania |
Aav-mediated expression of anti-inluenza antibodies and methods of use thereof
|
JP6831779B2
(ja)
|
2015-06-23 |
2021-02-17 |
ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia |
修飾された第ix因子、並びに、細胞、器官及び組織への遺伝子導入のための組成物、方法及び使用
|
EP3325018A4
(de)
|
2015-07-22 |
2019-04-24 |
Duke University |
Hochdurchsatz-screening von regulatorischen elementfunktionen mit epigenomeditierungstechnologien
|
CN108603235A
(zh)
*
|
2015-07-30 |
2018-09-28 |
马萨诸塞眼科耳科诊所 |
祖先病毒序列及其用途
|
EP4339287A3
(de)
|
2015-07-31 |
2024-05-22 |
Regents Of The University Of Minnesota |
Modifizierte zellen und therapieverfahren
|
WO2017024198A1
(en)
|
2015-08-06 |
2017-02-09 |
The Trustees Of The University Of Pennsylvania |
Glp-1 and use thereof in compositions for treating metabolic diseases
|
CA2996001A1
(en)
|
2015-08-25 |
2017-03-02 |
Duke University |
Compositions and methods of improving specificity in genomic engineering using rna-guided endonucleases
|
JP6877408B2
(ja)
|
2015-08-31 |
2021-05-26 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
ペット治療用aav−epo
|
US10988519B2
(en)
|
2015-09-24 |
2021-04-27 |
The Trustees Of The University Of Pennsylvania |
Composition and method for treating complement-mediated disease
|
WO2017062750A1
(en)
|
2015-10-09 |
2017-04-13 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods useful in treating stargardt's disease and other ocular disorders
|
EP4089175A1
(de)
|
2015-10-13 |
2022-11-16 |
Duke University |
Genom-engineering mit typ-i-crispr-systemen in eukaryotischen zellen
|
US11253576B2
(en)
|
2015-10-22 |
2022-02-22 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance in neurodegenerative disease
|
EP3364996B1
(de)
|
2015-10-22 |
2021-08-25 |
University of Massachusetts |
Gegen die prostata gerichtete adeno-assoziierte virusserotypvektoren
|
WO2017070476A2
(en)
*
|
2015-10-22 |
2017-04-27 |
University Of Florida Research Foundation, Inc. |
Synthetic combinatorial aav3 capsid library
|
BR112018008407A2
(pt)
|
2015-10-28 |
2018-11-27 |
Univ Pennsylvania |
administração intratecal de vetores virais adenoassociados para terapia genética
|
US20180230489A1
(en)
|
2015-10-28 |
2018-08-16 |
Voyager Therapeutics, Inc. |
Regulatable expression using adeno-associated virus (aav)
|
AU2016362477A1
(en)
|
2015-12-02 |
2018-06-14 |
Voyager Therapeutics, Inc. |
Assays for the detection of AAV neutralizing antibodies
|
KR20180097631A
(ko)
|
2015-12-11 |
2018-08-31 |
매사추세츠 아이 앤드 이어 인퍼머리 |
핵산을 와우 및 전정 세포에 전달하기 위한 물질 및 방법
|
EP3992283A1
(de)
|
2015-12-11 |
2022-05-04 |
The Trustees Of The University Of Pennsylvania |
Skalierbares reinigungsverfahren für aavrh10
|
WO2017160360A2
(en)
|
2015-12-11 |
2017-09-21 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav9
|
MA43570A
(fr)
|
2015-12-11 |
2018-11-14 |
Univ Pennsylvania |
Thérapie génique pour traiter l'hypercholestérolémie familiale
|
EP3387117B1
(de)
|
2015-12-11 |
2022-11-23 |
The Trustees Of The University Of Pennsylvania |
Skalierbares reinigungsverfahren für aav8
|
US11015173B2
(en)
|
2015-12-11 |
2021-05-25 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for AAV1
|
BR112018011838A2
(pt)
|
2015-12-14 |
2018-12-04 |
The Trustees Of The University Of Pennsylvania |
terapia gênica para distúrbios oculares
|
US11124546B2
(en)
*
|
2015-12-14 |
2021-09-21 |
The University Of North Carolina At Chapel Hill |
Modified capsid proteins for enhanced delivery of parvovirus vectors
|
AU2016370590B2
(en)
|
2015-12-14 |
2023-11-02 |
The Trustees Of The University Of Pennsylvania |
Composition for treatment of Crigler-Najjar syndrome
|
GB2545763A
(en)
|
2015-12-23 |
2017-06-28 |
Adverum Biotechnologies Inc |
Mutant viral capsid libraries and related systems and methods
|
EP3411059A4
(de)
*
|
2016-02-02 |
2019-10-16 |
University Of Massachusetts |
Verfahren zur erhöhung der wirksamkeit der systemischen abgabe von avv-genen an das zentrale nervensystem
|
SG11201806270XA
(en)
|
2016-02-03 |
2018-08-30 |
Univ Pennsylvania |
Gene therapy for treating mucopolysaccharidosis type i
|
EP3443001A4
(de)
|
2016-04-11 |
2020-04-29 |
Obsidian Therapeutics, Inc. |
Regulierte bioschaltkreissysteme
|
US11413356B2
(en)
|
2016-04-15 |
2022-08-16 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance
|
IL298604A
(en)
|
2016-04-15 |
2023-01-01 |
Univ Pennsylvania |
Novel aav8 mutant capsids and preparations containing them
|
SG11201808426XA
(en)
|
2016-04-15 |
2018-10-30 |
Univ Pennsylvania |
Compositions for treatment of wet age-related macular degeneration
|
IL305449A
(en)
|
2016-04-15 |
2023-10-01 |
Univ Pennsylvania |
Gene therapy for the treatment of type II mucositis
|
WO2017184463A1
(en)
|
2016-04-17 |
2017-10-26 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods useful for prophylaxis of organophosphates
|
WO2017189959A1
(en)
|
2016-04-29 |
2017-11-02 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
EP3448987A4
(de)
|
2016-04-29 |
2020-05-27 |
Voyager Therapeutics, Inc. |
Zusammensetzungen zur behandlung einer erkrankung
|
MA44740A
(fr)
|
2016-05-13 |
2019-02-27 |
4D Molecular Therapeutics Inc |
Variantes de capsides de virus adéno-associé et leurs procédés d'utilisation
|
MX2018014154A
(es)
|
2016-05-18 |
2019-05-06 |
Voyager Therapeutics Inc |
Polinucleotidos moduladores.
|
RU2764587C2
(ru)
|
2016-05-18 |
2022-01-18 |
Вояджер Терапьютикс, Инк. |
Способы и композиции для лечения хореи гентингтона
|
RU2764919C2
(ru)
|
2016-06-13 |
2022-01-24 |
Дзе Юниверсити Оф Норт Каролина Эт Чепел Хилл |
Оптимизированные гены и экспрессионные кассеты cln1, и их применение
|
WO2017218852A1
(en)
|
2016-06-15 |
2017-12-21 |
University Of Massachusetts |
Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
|
KR102526506B1
(ko)
|
2016-07-08 |
2023-05-03 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
Rdh12가 연루된 장애 및 질환의 치료를 위한 방법 및 조성물
|
US11883470B2
(en)
|
2016-07-25 |
2024-01-30 |
The Trustees Of The University Of Pennsylvania |
Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof
|
MX2019000962A
(es)
|
2016-07-26 |
2019-08-01 |
Biomarin Pharm Inc |
Novedosas proteinas de la capside del virus adenoasociado.
|
KR20230039779A
(ko)
|
2016-07-29 |
2023-03-21 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
변이체 캡시드를 갖는 아데노-관련된 바이러스 비리온 및 이의 사용 방법
|
EP3831281A1
(de)
|
2016-08-30 |
2021-06-09 |
The Regents of The University of California |
Verfahren für biomedizinisches targeting und freisetzung sowie vorrichtungen und systeme zur ausführung davon
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
WO2018064624A1
(en)
|
2016-09-29 |
2018-04-05 |
University Of Florida Research Foundation, Incorporated |
Aavrh.10 variants with host antibody escape capabilities and altered tissue targeting properties
|
EP3526333A4
(de)
|
2016-10-13 |
2020-07-29 |
University of Massachusetts |
Aav-capsid-designs
|
EP3529359B1
(de)
|
2016-10-18 |
2023-12-13 |
Regents of the University of Minnesota |
Tumorinfiltrierende lymphozyten zur verwendung in der therapie
|
WO2018075798A1
(en)
|
2016-10-19 |
2018-04-26 |
Adverum Biotechnologies, Inc. |
Modified aav capsids and uses thereof
|
EP3548065B1
(de)
|
2016-12-01 |
2022-11-09 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Pharmazeutische zusammensetzungen zur behandlung von degenerativen netzhauterkrankungen
|
WO2018139634A1
(ja)
*
|
2017-01-30 |
2018-08-02 |
学校法人日本医科大学 |
アデノ随伴ウイルス(aav)キャプシドタンパク質の変異体
|
AU2018220212A1
(en)
|
2017-02-20 |
2019-08-08 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating familial hypercholesterolemia
|
CA3054131C
(en)
|
2017-02-21 |
2021-05-25 |
University Of Florida Research Foundation, Incorporated |
Modified aav capsid proteins and uses thereof
|
HRP20240257T1
(hr)
|
2017-02-28 |
2024-05-24 |
The Trustees Of The University Of Pennsylvania |
Adeno-povezani virusni (aav) clade f vektor i njegova uporaba
|
SG11201907611WA
(en)
|
2017-02-28 |
2019-09-27 |
Univ Pennsylvania |
Influenza vaccines based on aav vectors
|
JOP20190200A1
(ar)
|
2017-02-28 |
2019-08-27 |
Univ Pennsylvania |
تركيبات نافعة في معالجة ضمور العضل النخاعي
|
BR112019017327A2
(pt)
|
2017-03-01 |
2020-04-14 |
Univ Pennsylvania |
terapia gênica para distúrbios oculares
|
BR112019021569A2
(pt)
|
2017-04-14 |
2020-05-12 |
Regenxbio Inc. |
Precursor de iduronato-2-sulfatase humana recombinante glicosilada (ids), método para tratar um sujeito humano diagnosticado com mucopolissacaridose tipo ii (mps ii)
|
US11879133B2
(en)
|
2017-04-24 |
2024-01-23 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for ocular disorders
|
EP3619308A4
(de)
|
2017-05-05 |
2021-01-27 |
Voyager Therapeutics, Inc. |
Zusammensetzungen und verfahren zur behandlung von morbus huntington
|
AU2018261790A1
(en)
|
2017-05-05 |
2019-11-28 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
|
JP7330899B2
(ja)
|
2017-05-10 |
2023-08-22 |
マサチューセッツ アイ アンド イヤー インファーマリー |
ウイルスのアセンブリ活性化タンパク質(aap)依存性を改変する方法および組成物
|
KR20200023280A
(ko)
|
2017-05-11 |
2020-03-04 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
신경 세로이드 지질갈색소증에 대한 유전자 요법
|
CN108103082B
(zh)
*
|
2017-05-11 |
2021-07-13 |
北京锦篮基因科技有限公司 |
一种腺相关病毒介导的lcat基因表达载体及其用途
|
US11793887B2
(en)
|
2017-05-31 |
2023-10-24 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating peroxisomal disorders
|
WO2018232149A1
(en)
|
2017-06-14 |
2018-12-20 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for ocular disorders
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
JP2020530307A
(ja)
|
2017-06-30 |
2020-10-22 |
インティマ・バイオサイエンス,インコーポレーテッド |
遺伝子治療のためのアデノ随伴ウイルスベクター
|
BR112020000063A2
(pt)
|
2017-07-06 |
2020-07-14 |
The Trustees Of The University Of Pennsylvania |
terapia gênica mediada por aav9 para tratamento de mucopolissacaridose tipo i
|
WO2019018342A1
(en)
|
2017-07-17 |
2019-01-24 |
Voyager Therapeutics, Inc. |
NETWORK EQUIPMENT TRACK GUIDE SYSTEM
|
WO2019028306A2
(en)
|
2017-08-03 |
2019-02-07 |
Voyager Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR ADMINISTRATION OF ADENO-ASSOCIATED VIRUSES
|
KR20200042935A
(ko)
*
|
2017-08-25 |
2020-04-24 |
오비드 테라퓨틱스 인크. |
재조합 아데노-관련된 벡터들
|
CN110709511A
(zh)
|
2017-08-28 |
2020-01-17 |
加利福尼亚大学董事会 |
腺相关病毒衣壳变体及其使用方法
|
PT3684423T
(pt)
*
|
2017-09-20 |
2023-06-09 |
4D Molecular Therapeutics Inc |
Cápsides variantes de vírus adeno-associado e métodos de utilização das mesmas
|
CA3076036A1
(en)
|
2017-09-22 |
2019-03-28 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating mucopolysaccharidosis type ii
|
WO2019079242A1
(en)
|
2017-10-16 |
2019-04-25 |
Voyager Therapeutics, Inc. |
TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
|
EP4124658A3
(de)
|
2017-10-16 |
2023-04-19 |
Voyager Therapeutics, Inc. |
Behandlung von amyotropher lateralsklerose (als)
|
SG11202003479TA
(en)
|
2017-10-18 |
2020-05-28 |
Regenxbio Inc |
Fully-human post-translationally modified antibody therapeutics
|
CA3079565A1
(en)
|
2017-10-18 |
2019-04-25 |
Regenxbio Inc. |
Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified vegf-trap
|
EP3717636B1
(de)
|
2017-11-27 |
2023-03-08 |
4D Molecular Therapeutics Inc. |
Adeno-assoziierte virusvarianten kapside und verwendung zur hemmung der angiogenese
|
EP3717652A4
(de)
|
2017-11-30 |
2021-11-24 |
The Trustees of the University of Pennsylvania |
Gentherapie für mucopolysaccharidose iiib
|
CA3083416A1
(en)
|
2017-11-30 |
2019-06-06 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for mucopolysaccharidosis iii a
|
SG11202005618WA
(en)
|
2017-12-19 |
2020-07-29 |
Akouos Inc |
Aav-mediated delivery of therapeutic antibodies to the inner ear
|
US10806802B2
(en)
|
2018-01-18 |
2020-10-20 |
University Of Guelph |
Adeno-associated virus particle with mutated capsid and methods of use thereof
|
US10610606B2
(en)
|
2018-02-01 |
2020-04-07 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
|
WO2019161365A1
(en)
|
2018-02-19 |
2019-08-22 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for restoring f8 gene function and methods of use thereof
|
CA3091806A1
(en)
*
|
2018-02-27 |
2019-09-06 |
The Trustees Of The University Of Pennsylvania |
Novel adeno-associated virus (aav) vectors, aav vectors having reduced capsid deamidation and uses therefor
|
BR112020017278A2
(pt)
*
|
2018-02-27 |
2020-12-22 |
The Trustees Of The University Of Pennsylvania |
Vetores de vírus adenoassociado (aav), vetores de aav tendo desamidação de capsídeos reduzida e usos para os mesmos
|
CA3095127A1
(en)
*
|
2018-03-29 |
2019-10-03 |
Asklepios Biopharmaceutical, Inc. |
Liver tropic recombinant aav6 vectors that evade neutralization
|
TN2020000187A1
(en)
|
2018-04-05 |
2022-04-04 |
Univ Devry Val Dessonne |
Hybrid recombinant adeno-associated virus serotype between aav9 and aavrh74 with reduced liver tropism
|
EP3788165A1
(de)
|
2018-04-29 |
2021-03-10 |
REGENXBIO Inc. |
Systeme und verfahren zur spektralfotometrie zur bestimmung des genomgehalts, des kapsidgehalts und der voll-/leer-verhältnisse von adeno-assoziierten viruspartikeln
|
EP3787771A1
(de)
|
2018-04-29 |
2021-03-10 |
REGENXBIO Inc. |
Skalierbares klärungsverfahren für die rekombinante aav-produktion
|
CN112154209A
(zh)
|
2018-05-08 |
2020-12-29 |
罗特格斯新泽西州立大学 |
Aav相容的层粘连蛋白—连接子聚合蛋白
|
TW202005978A
(zh)
|
2018-05-14 |
2020-02-01 |
美商拜奧馬林製藥公司 |
新穎肝靶向腺相關病毒載體
|
SG11202011296VA
(en)
|
2018-05-15 |
2020-12-30 |
Voyager Therapeutics Inc |
Compositions and methods for the treatment of parkinson's disease
|
TW202015742A
(zh)
|
2018-05-15 |
2020-05-01 |
美商航海家醫療公司 |
投遞腺相關病毒(aav)之組成物和方法
|
EP3806888B1
(de)
|
2018-06-12 |
2024-01-31 |
Obsidian Therapeutics, Inc. |
Von pde5 abgeleitete regulatorische konstrukte und verfahren zur verwendung in der immuntherapie
|
EP3807404A1
(de)
|
2018-06-13 |
2021-04-21 |
Voyager Therapeutics, Inc. |
Manipulierte 5'-unübersetzte regionen (5' utr) zur herstellung von aav
|
US20210370199A1
(en)
|
2018-06-14 |
2021-12-02 |
Regenxbio Inc. |
Anion exchange chromatography for recombinant aav production
|
GB201811368D0
(en)
|
2018-07-11 |
2018-08-29 |
Ucb Biopharma Sprl |
Antibody
|
JP2021530548A
(ja)
|
2018-07-24 |
2021-11-11 |
ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics, Inc. |
遺伝子治療製剤を生産するための系および方法
|
CA3108113A1
(en)
|
2018-08-10 |
2020-02-13 |
Michael GILLMEISTER |
Scalable method for recombinant aav production
|
US10842885B2
(en)
|
2018-08-20 |
2020-11-24 |
Ucl Business Ltd |
Factor IX encoding nucleotides
|
BR112021003897A2
(pt)
|
2018-08-30 |
2021-05-25 |
Tenaya Therapeutics, Inc. |
reprogramação de células cardíacas com miocarina e asci1
|
SG11202103151RA
(en)
|
2018-09-28 |
2021-04-29 |
Voyager Therapeutics Inc |
Frataxin expression constructs having engineered promoters and methods of use thereof
|
BR112021006060A2
(pt)
|
2018-10-01 |
2021-07-20 |
The Trustees Of The University Of Pennsylvania |
composições úteis para tratamento de gangliosidose gm1
|
TW202035689A
(zh)
|
2018-10-04 |
2020-10-01 |
美商航海家醫療公司 |
測量病毒載體粒子的效價及強度之方法
|
US20210348194A1
(en)
|
2018-10-05 |
2021-11-11 |
Voyager Therapeutics, Inc. |
Engineered nucleic acid constructs encoding aav production proteins
|
WO2020077165A1
(en)
|
2018-10-12 |
2020-04-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
US20210395777A1
(en)
|
2018-10-15 |
2021-12-23 |
Voyager Therapeutics, Inc. |
EXPRESSION VECTORS FOR LARGE-SCALE PRODUCTION OF rAAV IN THE BACULOVIRUS/Sf9 SYSTEM
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
CA3115524A1
(en)
|
2018-10-15 |
2020-04-23 |
Win Den Cheung |
Methods for measuring the infectivity of replication defective viral vectors and viruses
|
EP3870600A1
(de)
|
2018-10-24 |
2021-09-01 |
Obsidian Therapeutics, Inc. |
Er-abstimmbare proteinregulierung
|
HRP20231750T1
(hr)
|
2019-01-04 |
2024-05-24 |
Ultragenyx Pharmaceutical Inc. |
Konstrukti genske terapije za liječenje wilsonove bolesti
|
EP3911410A1
(de)
|
2019-01-18 |
2021-11-24 |
Voyager Therapeutics, Inc. |
Verfahren und systeme zur herstellung von aav-partikeln
|
EP3914229A4
(de)
*
|
2019-01-23 |
2022-11-02 |
University of Florida Research Foundation, Incorporated |
Hocheffiziente transduktion und laterale ausbreitung in der netzhaut durch ein neuartiges verstärktes aav-virus mit rationalem design
|
US20230193315A1
(en)
|
2019-01-31 |
2023-06-22 |
Oregon Health & Science University |
Methods for using transcription-dependent directed evolution of aav capsids
|
CN113710281A
(zh)
|
2019-02-22 |
2021-11-26 |
宾夕法尼亚州大学信托人 |
用于治疗grn相关成人发作性神经退行性病变的重组腺相关病毒
|
CA3130731A1
(en)
|
2019-02-25 |
2020-09-03 |
Friedrich Miescher Institute For Biomedical Research |
Compositions and methods to treat bietti crystalline dystrophy
|
JP2022520875A
(ja)
|
2019-02-25 |
2022-04-01 |
ノバルティス アーゲー |
Biettiクリスタリン網膜症を治療するための組成物及び方法
|
SG11202108480UA
(en)
|
2019-02-26 |
2021-09-29 |
Univ Pennsylvania |
Compositions useful in treatment of krabbe disease
|
CN113966236A
(zh)
|
2019-04-03 |
2022-01-21 |
再生生物股份有限公司 |
眼睛病状的基因疗法
|
TW202102526A
(zh)
|
2019-04-04 |
2021-01-16 |
美商銳進科斯生物股份有限公司 |
重組腺相關病毒及其用途
|
DK3953483T3
(da)
|
2019-04-11 |
2023-12-18 |
Regenxbio Inc |
Fremgangsmåder til størrelseskromatografi til karakterisering af sammensætninger af rekombinant adeno-associeret virus
|
MX2021012564A
(es)
|
2019-04-19 |
2022-01-18 |
Regenxbio Inc |
Formulaciones y métodos de vectores de virus adenoasociados.
|
EP3959325A2
(de)
*
|
2019-04-23 |
2022-03-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Neue varianten des adeno-assoziierten virus (aav) und verwendungen davon zur gentherapie
|
TW202106708A
(zh)
|
2019-04-24 |
2021-02-16 |
美商銳進科斯生物股份有限公司 |
全人類轉譯後修飾之抗體治療劑
|
EP3752524A4
(de)
*
|
2019-04-27 |
2021-11-24 |
Ocugen, Inc. |
Durch adeno-assoziierten virusvektor vermittelte gentherapie für ophthalmische krankheit
|
JP2022530633A
(ja)
*
|
2019-04-29 |
2022-06-30 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
新規aavカプシドおよびそれを含む組成物
|
WO2020227515A1
(en)
|
2019-05-07 |
2020-11-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
|
US20220251567A1
(en)
|
2019-07-10 |
2022-08-11 |
Inserm (Institut National De La Santè Et De La Recherche Médicale) |
Methods for the treatment of epilepsy
|
EP3997226A1
(de)
|
2019-07-11 |
2022-05-18 |
Tenaya Therapeutics, Inc. |
Umprogrammierung von herzzellen mit mikrornas und anderen faktoren
|
AU2020314883A1
(en)
*
|
2019-07-15 |
2022-03-03 |
Meiragtx Uk Ii Limited |
Modified AAV capsid proteins for treatment of arthritic disease
|
WO2021021674A1
(en)
|
2019-07-26 |
2021-02-04 |
Akouos, Inc. |
Methods of treating hearing loss using a secreted target protein
|
WO2021021661A1
(en)
|
2019-07-26 |
2021-02-04 |
Regenxbio Inc. |
Engineered nucleic acid regulatory element and methods of uses thereof
|
JP2022545967A
(ja)
|
2019-08-26 |
2022-11-01 |
リジェネックスバイオ インコーポレイテッド |
完全ヒト翻訳後修飾抗VEGF Fabを用いる糖尿病性網膜症の処置
|
WO2021040736A1
(en)
|
2019-08-30 |
2021-03-04 |
Obsidian Therapeutics, Inc. |
Tandem cd19 car-based compositions and methods for immunotherapy
|
US20220333133A1
(en)
|
2019-09-03 |
2022-10-20 |
Voyager Therapeutics, Inc. |
Vectorized editing of nucleic acids to correct overt mutations
|
WO2021046451A1
(en)
|
2019-09-06 |
2021-03-11 |
Obsidian Therapeutics, Inc. |
Compositions and methods for dhfr tunable protein regulation
|
US20220340643A1
(en)
|
2019-09-13 |
2022-10-27 |
Rutgers, The State University Of New Jersey |
Aav-compatible laminin-linker polymerization proteins
|
US20220347298A1
(en)
|
2019-10-04 |
2022-11-03 |
Ultragenyx Pharmaceutical Inc. |
Methods for improved therapeutic use of recombinant aav
|
KR20220081365A
(ko)
|
2019-10-07 |
2022-06-15 |
리젠엑스바이오 인크. |
아데노-연관 바이러스 벡터 약제학적 조성물 및 방법
|
WO2021073568A1
(en)
*
|
2019-10-16 |
2021-04-22 |
Wuxi Apptec (Shanghai) Co., Ltd. |
A novel aav variant
|
US20230016983A1
(en)
|
2019-11-19 |
2023-01-19 |
lNSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) |
Antisense oligonucleotides and thier use for the treatment of cancer
|
KR20220107222A
(ko)
|
2019-11-28 |
2022-08-02 |
리젠엑스바이오 인크. |
마이크로디스트로핀 유전자 치료 작제물 및 이의 용도
|
IL293684A
(en)
|
2019-12-10 |
2022-08-01 |
Takeda Pharmaceuticals Co |
Adeno-related virus vectors for the treatment of Hunter disease
|
CA3161367A1
(en)
*
|
2019-12-10 |
2021-06-17 |
Homology Medicines, Inc. |
Adeno-associated virus compositions and methods of use thereof
|
TW202140791A
(zh)
|
2020-01-13 |
2021-11-01 |
美商霍蒙拉奇醫藥公司 |
治療苯酮尿症之方法
|
EP4093428A1
(de)
|
2020-01-22 |
2022-11-30 |
RegenxBio Inc. |
Behandlung von mucopolysaccharidose i mit vollständig menschlicher glykosylierter menschlicher alpha-l-iduronidase (idua)
|
TW202136516A
(zh)
|
2020-01-29 |
2021-10-01 |
美商銳進科斯生物股份有限公司 |
Iva型黏多醣病之治療
|
US20230088992A1
(en)
|
2020-01-29 |
2023-03-23 |
Regenxbio Inc. |
Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids) produced by human neural or glial cells
|
IL294924A
(en)
|
2020-02-02 |
2022-09-01 |
Univ Pennsylvania |
Useful preparations for the treatment of gm1 gangliosidosis
|
BR112022015921A2
(pt)
|
2020-02-14 |
2022-10-04 |
Ultragenyx Pharmaceutical Inc |
Terapia gênica para tratar o transtorno de deficiência de cdkl5
|
TW202142554A
(zh)
*
|
2020-02-25 |
2021-11-16 |
澳洲兒童醫學研究所 |
腺相關病毒蛋白殼多肽及載體
|
EP4121544A1
(de)
|
2020-03-19 |
2023-01-25 |
Ultragenyx Pharmaceutical Inc. |
Zusammensetzungen und verfahren zur verringerung der umgekehrten verpackung von cap- und rep-sequenzen in rekombinantem aav
|
CN115667298A
(zh)
|
2020-03-27 |
2023-01-31 |
Ucb生物制药有限责任公司 |
自主凸起结构域肽
|
US20230129893A1
(en)
|
2020-03-31 |
2023-04-27 |
Ultragenyx Pharmaceutical Inc. |
Gene therapy for treating propionic acidemia
|
US20230242940A1
(en)
*
|
2020-04-13 |
2023-08-03 |
Massachusetts Eye And Ear Infirmary |
Methods of making and using a vaccine against coronavirus
|
BR112022020753A2
(pt)
|
2020-04-15 |
2022-12-20 |
Voyager Therapeutics Inc |
Compostos de ligação a tau
|
JP2023526310A
(ja)
|
2020-05-12 |
2023-06-21 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
導入遺伝子発現のdrg特異的低減のための組成物
|
IL298137A
(en)
|
2020-05-12 |
2023-01-01 |
Univ Pennsylvania |
The compositions are useful in the treatment of Krabbe's disease
|
KR20230041965A
(ko)
|
2020-05-13 |
2023-03-27 |
아카우오스, 인크. |
Slc26a4-연관 청력손실을 치료하기 위한 조성물 및 방법
|
TW202208406A
(zh)
|
2020-05-13 |
2022-03-01 |
美商阿科奧斯公司 |
用於治療kcnq4相關性聽力損失之組成物及方法
|
AU2021282257A1
(en)
|
2020-05-26 |
2022-12-01 |
Shape Therapeutics Inc. |
High throughput engineering of functional AAV capsids
|
WO2021247995A2
(en)
|
2020-06-04 |
2021-12-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating neuropathic pain
|
WO2021257668A1
(en)
|
2020-06-17 |
2021-12-23 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of gene therapy patients
|
JP2023540429A
(ja)
|
2020-07-10 |
2023-09-25 |
アンセルム(アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル) |
てんかんを治療するための方法及び組成物
|
IL299762A
(en)
|
2020-07-13 |
2023-03-01 |
Univ Pennsylvania |
Useful preparations for the treatment of Charcot-Marietot disease
|
MX2023000815A
(es)
|
2020-07-27 |
2023-04-11 |
Voyager Therapeutics Inc |
Composiciones y metodos para el tratamiento de trastornos neurologicos relacionados con la deficiencia de glucosilceramidasa beta.
|
WO2022026410A2
(en)
|
2020-07-27 |
2022-02-03 |
Voyager Therapeutics, Inc |
Compositions and methods for the treatment of niemann-pick type c1 disease
|
CN115960921A
(zh)
*
|
2020-07-29 |
2023-04-14 |
舒泰神(北京)生物制药股份有限公司 |
一组肝靶向新型腺相关病毒的获得及其应用
|
US20220145328A1
(en)
|
2020-07-30 |
2022-05-12 |
Shape Therapeutics Inc. |
STABLE CELL LINES FOR INDUCIBLE PRODUCTION OF rAAV VIRIONS
|
WO2022046815A1
(en)
|
2020-08-24 |
2022-03-03 |
The Trustees Of The University Of Pennsylvania |
Viral vectors encoding glp-1 receptor agonist fusions and uses thereof in treating metabolic diseases
|
US20230364264A1
(en)
|
2020-08-26 |
2023-11-16 |
The Trustees Of The University Of Pennsylvania |
Recombinant adeno-associated virus for treatment of grn-associated adult-onset neurodegeneration
|
EP4214242A1
(de)
|
2020-09-15 |
2023-07-26 |
RegenxBio Inc. |
Vektorisierte antikörper für antivirale therapie
|
EP4213890A1
(de)
|
2020-09-15 |
2023-07-26 |
RegenxBio Inc. |
Vektorisierte lanadlumab und verabreichung davon
|
WO2022061002A1
(en)
|
2020-09-18 |
2022-03-24 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Novel adeno-associated viral (aav) vectors to treat hereditary methylmalonic acidemia (mma) caused by methylmalonyl-coa mutase (mmut) deficiency
|
WO2022076750A2
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns or muscle delivery
|
EP4225270A1
(de)
|
2020-10-07 |
2023-08-16 |
RegenxBio Inc. |
Formulierungen zur suprachoroidalen verabreichung wie hochviskose formulierungen
|
IL301947A
(en)
|
2020-10-07 |
2023-06-01 |
Regenxbio Inc |
Suprachoroid administration formulations, such as gel formulations
|
US20230381341A1
(en)
|
2020-10-07 |
2023-11-30 |
Regenxbio Inc. |
Adeno-associated viruses for ocular delivery of gene therapy
|
CA3197342A1
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Gene therapy for ocular manifestations of cln2 disease
|
CA3198368A1
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Formulations for suprachoroidal administration such as formulations with aggregate formation
|
US11781156B2
(en)
|
2020-10-09 |
2023-10-10 |
Tenaya Therapeutics, Inc. |
Plakophillin-2 gene therapy methods and compositions
|
US20230365955A1
(en)
|
2020-10-09 |
2023-11-16 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of fabry disease
|
CA3195553A1
(en)
|
2020-10-18 |
2022-04-21 |
Qiang Wang |
Improved adeno-associated virus (aav) vector and uses therefor
|
WO2022094078A1
(en)
|
2020-10-28 |
2022-05-05 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of rett syndrome
|
WO2022094157A1
(en)
|
2020-10-28 |
2022-05-05 |
Regenxbio Inc. |
Vectorized anti-cgrp and anti-cgrpr antibodies and administration thereof
|
CN116528892A
(zh)
|
2020-10-28 |
2023-08-01 |
再生生物股份有限公司 |
用于眼部适应症的载体化抗TNF-α抗体
|
WO2022094255A2
(en)
|
2020-10-29 |
2022-05-05 |
Regenxbio Inc. |
Vectorized factor xii antibodies and administration thereof
|
AU2021369833A1
(en)
|
2020-10-29 |
2023-06-08 |
Regenxbio Inc. |
Vectorized tnf-alpha antagonists for ocular indications
|
WO2022119890A1
(en)
|
2020-12-01 |
2022-06-09 |
The Trustees Of The University Of Pennsylvania |
Compositions and uses thereof for treatment of angelman syndrome
|
TW202237850A
(zh)
|
2020-12-01 |
2022-10-01 |
賓州大學委員會 |
具有組織特異性靶向基序的新穎構成物及含有其之組成物
|
MX2023006451A
(es)
|
2020-12-01 |
2023-06-15 |
Akouos Inc |
Construcciones de anticuerpos anti-vegf y metodos relacionados para el tratamiento de los sintomas asociados al schwannoma vestibular.
|
IL303614A
(en)
|
2020-12-16 |
2023-08-01 |
Regenxbio Inc |
A method for producing an ADNO-linked recombinant virus particle
|
EP4271419A1
(de)
|
2020-12-29 |
2023-11-08 |
Akouos, Inc. |
Zusammensetzungen und verfahren zur behandlung von clrn1-assoziiertem hörverlust und/oder sehverlust
|
WO2022147087A1
(en)
|
2020-12-29 |
2022-07-07 |
Regenxbio Inc. |
Tau-specific antibody gene therapy compositions, methods and uses thereof
|
MX2023008595A
(es)
|
2021-01-21 |
2023-09-14 |
Regenxbio Inc |
Produccion mejorada de polipeptidos y virus recombinantes.
|
CA3209779A1
(en)
|
2021-02-01 |
2022-08-04 |
Regenxbio Inc. |
Gene therapy for neuronal ceroid lipofuscinoses
|
WO2022169774A1
(en)
|
2021-02-02 |
2022-08-11 |
University Of Massachusetts |
Inverted terminal repeats from aav serotypes 8 and rh.39 in gene therapy vectors
|
WO2022173605A2
(en)
|
2021-02-10 |
2022-08-18 |
Regenxbio Inc. |
Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids)
|
CA3209673A1
(en)
|
2021-02-26 |
2022-09-01 |
Rizwana ISLAM |
Composition and methods for the treatment of fabry disease
|
JP2024515612A
(ja)
|
2021-04-12 |
2024-04-10 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
球脊髄性筋萎縮症(sbma)の治療に有用な組成物
|
AR125406A1
(es)
|
2021-04-23 |
2023-07-12 |
Univ Pennsylvania |
Nuevas composiciones con motivos selectivos para el cerebro y composiciones que las contienen
|
JP2024515715A
(ja)
|
2021-04-23 |
2024-04-10 |
ユニバーシティ オブ ロチェスター |
レトロウイルスインテグラーゼ-Cas融合タンパク質を使用した指向性非相同DNA挿入によるゲノム編集及び治療の方法
|
JP2024517143A
(ja)
|
2021-04-26 |
2024-04-19 |
リジェネックスバイオ インコーポレイテッド |
ジストロフィン異常症の治療のためのマイクロジストロフィン遺伝子療法投与
|
WO2022235614A2
(en)
|
2021-05-04 |
2022-11-10 |
Regenxbio Inc. |
Novel aav vectors and methods and uses thereof
|
EP4337267A1
(de)
|
2021-05-11 |
2024-03-20 |
RegenxBio Inc. |
Behandlung von duchenne-muskeldystrophie und kombinationen davon
|
JP2024522876A
(ja)
|
2021-06-25 |
2024-06-21 |
オックスフォード バイオメディカ ソリューションズ エルエルシー |
アデノ随伴ウイルスパッケージングシステム
|
AU2022301302A1
(en)
|
2021-07-01 |
2024-01-25 |
Indapta Therapeutics, Inc. |
Engineered natural killer (nk) cells and related methods
|
AU2022313258A1
(en)
|
2021-07-19 |
2024-02-08 |
New York University |
Auf1 combination therapies for treatment of muscle degenerative disease
|
AU2022325955A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
|
EP4384544A1
(de)
|
2021-08-11 |
2024-06-19 |
Sana Biotechnology, Inc. |
Genetisch modifizierte zellen für allogene zelltherapie
|
IL310691A
(en)
|
2021-08-11 |
2024-04-01 |
Sana Biotechnology Inc |
Genetically modified primary cells for allogeneic cell therapy
|
WO2023019168A1
(en)
|
2021-08-11 |
2023-02-16 |
Ultragenyx Pharmaceutical Inc. |
Compositions and methods for treating a muscular dystrophy
|
AU2022325231A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
|
WO2023028513A1
(en)
|
2021-08-24 |
2023-03-02 |
Oxford Biomedica Solutions Llc |
Adeno-associated virus formulations
|
CN118159663A
(zh)
*
|
2021-08-25 |
2024-06-07 |
北海康成制药有限公司 |
包含嗜肝衣壳蛋白和酸性α-葡糖苷酶(GAA)的AAV颗粒及其治疗庞贝病的用途
|
IL311572A
(en)
|
2021-09-30 |
2024-05-01 |
Akouos Inc |
Compositions and methods for treating KCNQ4-related hearing loss
|
TW202325845A
(zh)
|
2021-10-02 |
2023-07-01 |
賓州大學委員會 |
新穎aav衣殼及含其之組成物
|
CN118202060A
(zh)
|
2021-10-05 |
2024-06-14 |
再生生物股份有限公司 |
用于重组aav生产的组合物和方法
|
WO2023060113A1
(en)
|
2021-10-05 |
2023-04-13 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
WO2023060269A1
(en)
|
2021-10-07 |
2023-04-13 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for targeted delivery
|
WO2023060272A2
(en)
|
2021-10-07 |
2023-04-13 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns tropic delivery
|
WO2023077092A1
(en)
|
2021-10-28 |
2023-05-04 |
Regenxbio Inc. |
Engineered nucleic acid regulatory elements and methods and uses thereof
|
US20230183658A1
(en)
|
2021-10-29 |
2023-06-15 |
Oxford Biomedica Solutions Llc |
Methods and compositions for the purification of adeno-associated virus
|
WO2023087019A2
(en)
|
2021-11-15 |
2023-05-19 |
The Trustees Of The University Of Pennsylvania |
Compositions for drg-specific reduction of transgene expression
|
CA3239452A1
(en)
|
2021-12-01 |
2023-06-08 |
Thomas Packard |
Functional aav capsids for systemic administration
|
AU2022399440A1
(en)
|
2021-12-01 |
2024-06-20 |
Shape Therapeutics Inc. |
Functional aav capsids for intravitreal administration
|
WO2023102517A1
(en)
|
2021-12-02 |
2023-06-08 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of fabry disease
|
WO2023106256A1
(ja)
*
|
2021-12-06 |
2023-06-15 |
学校法人順天堂 |
改変型アデノ随伴ウイルスベクター
|
WO2023114901A2
(en)
|
2021-12-15 |
2023-06-22 |
Oxford Biomedica Solutions Llc |
Methods and compositions for the production of adeno-associated virus
|
WO2023133595A2
(en)
|
2022-01-10 |
2023-07-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
WO2023133574A1
(en)
|
2022-01-10 |
2023-07-13 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods useful for treatment of c9orf72-mediated disorders
|
WO2023133584A1
(en)
|
2022-01-10 |
2023-07-13 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of metachromatic leukodystrophy
|
WO2023147304A1
(en)
|
2022-01-25 |
2023-08-03 |
The Trustees Of The University Of Pennsylvania |
Aav capsids for improved heart transduction and detargeting of liver
|
TW202342525A
(zh)
|
2022-02-02 |
2023-11-01 |
美商阿科奧斯公司 |
用於治療前庭神經鞘瘤相關症狀之抗vegf抗體構築體及相關方法
|
WO2023150647A1
(en)
|
2022-02-02 |
2023-08-10 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
WO2023158836A1
(en)
|
2022-02-17 |
2023-08-24 |
Sana Biotechnology, Inc. |
Engineered cd47 proteins and uses thereof
|
TW202342740A
(zh)
|
2022-03-07 |
2023-11-01 |
美商奧崔基尼克斯製藥公司 |
改良的批量aav生產系統和方法
|
WO2023173123A1
(en)
|
2022-03-11 |
2023-09-14 |
Sana Biotechnology, Inc. |
Genetically modified cells and compositions and uses thereof
|
TW202346590A
(zh)
|
2022-03-13 |
2023-12-01 |
美商銳進科斯生物股份有限公司 |
經修飾之肌肉特異性啟動子
|
WO2023183623A1
(en)
|
2022-03-25 |
2023-09-28 |
Regenxbio Inc. |
Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy
|
WO2023187728A1
(en)
|
2022-04-01 |
2023-10-05 |
Takeda Pharmaceutical Company Limited |
Gene therapy for diseases with cns manifestations
|
WO2023196892A1
(en)
|
2022-04-06 |
2023-10-12 |
The Trustees Of The University Of Pennsylvania |
Passive immunization with anti- aav neutralizing antibodies to prevent off-target transduction of intrathecally delivered aav vectors
|
TW202345913A
(zh)
|
2022-04-06 |
2023-12-01 |
美商銳進科斯生物股份有限公司 |
用於脈絡膜上投與之調配物諸如凝膠調配物
|
TW202404651A
(zh)
|
2022-04-06 |
2024-02-01 |
美商銳進科斯生物股份有限公司 |
用於脈絡膜上投與之調配物諸如形成聚集體之調配物
|
WO2023196873A1
(en)
|
2022-04-06 |
2023-10-12 |
Regenxbio Inc. |
Pharmaceutical composition comprising a recombinant adeno-associated virus vector with an expression cassette encoding a transgene forsuprachoidal administration
|
WO2023196893A1
(en)
|
2022-04-06 |
2023-10-12 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treating her2 positive metastatic breast cancer and other cancers
|
WO2023201308A1
(en)
|
2022-04-14 |
2023-10-19 |
Regenxbio Inc. |
Gene therapy for treating an ocular disease
|
WO2023201277A1
(en)
|
2022-04-14 |
2023-10-19 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns tropic delivery
|
WO2023215806A2
(en)
|
2022-05-03 |
2023-11-09 |
Regenxbio Inc. |
Vectorized anti-complement antibodies and complement agents and administration thereof
|
WO2023215807A1
(en)
|
2022-05-03 |
2023-11-09 |
Regenxbio Inc. |
VECTORIZED ANTI-TNF-α INHIBITORS FOR OCULAR INDICATIONS
|
WO2023214346A1
(en)
|
2022-05-06 |
2023-11-09 |
Novartis Ag |
Novel recombinant aav vp2 fusion polypeptides
|
WO2023239627A2
(en)
|
2022-06-08 |
2023-12-14 |
Regenxbio Inc. |
Methods for recombinant aav production
|
WO2024007020A1
(en)
|
2022-06-30 |
2024-01-04 |
Indapta Therapeutics, Inc. |
Combination of engineered natural killer (nk) cells and antibody therapy and related methods
|
WO2024017990A1
(en)
|
2022-07-21 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating chronic pain disorders
|
WO2024026377A1
(en)
|
2022-07-27 |
2024-02-01 |
Sana Biotechnology, Inc. |
Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
|
WO2024044725A2
(en)
|
2022-08-24 |
2024-02-29 |
Regenxbio Inc. |
Recombinant adeno-associated viruses and uses thereof
|
TW202413648A
(zh)
|
2022-08-25 |
2024-04-01 |
日商武田藥品工業股份有限公司 |
用於治療法布立氏病(fabry disease)之組合物及方法
|
WO2024073669A1
(en)
|
2022-09-30 |
2024-04-04 |
Regenxbio Inc. |
Treatment of ocular diseases with recombinant viral vectors encoding anti-vegf fab
|
CN115960177B
(zh)
*
|
2022-10-09 |
2023-07-07 |
广州派真生物技术有限公司 |
腺相关病毒突变体及其应用
|
WO2024081746A2
(en)
|
2022-10-11 |
2024-04-18 |
Regenxbio Inc. |
Engineered nucleic acid regulatory elements and methods and uses thereof
|
WO2024105638A1
(en)
|
2022-11-18 |
2024-05-23 |
Jcr Pharmaceuticals Co., Ltd. |
Recombinant aav vectors and methods for treatment of hunter syndrome
|
CN115838399B
(zh)
*
|
2022-12-08 |
2023-08-11 |
广州派真生物技术有限公司 |
腺相关病毒突变体及其应用
|
WO2024130070A2
(en)
|
2022-12-17 |
2024-06-20 |
The Trustees Of The University Of Pennsylvania |
Recombinant aav capsids with cardiac- and skeletal muscle- specific targeting motifs and uses thereof
|
WO2024130067A2
(en)
|
2022-12-17 |
2024-06-20 |
The Trustees Of The University Of Pennsylvania |
Recombinant aav mutant vectors with cardiac and skeletal muscle-specific targeting motifs and compositions containing same
|
WO2024134525A1
(en)
|
2022-12-22 |
2024-06-27 |
Fondazione Telethon Ets |
Lsd1 inhibitor and prmt6 inhibitor for use in the treatment of a disease associated with gain-of-function of androgen receptor (ar) and/or with overexpression of an ar coactivator
|